Patents by Inventor Joan Massague
Joan Massague has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230190963Abstract: The present invention relates to methods and compositions for inhibiting metastatic spread of cancer and/or inhibiting progression of pre-existing metastatic disease in a subject using L1CAM inhibition.Type: ApplicationFiled: October 10, 2022Publication date: June 22, 2023Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Karuna Ganesh, Manuel Valiente, Joan Massague
-
Patent number: 11464874Abstract: The present invention relates to methods and compositions for inhibiting metastatic spread of cancer and/or inhibiting progression of pre-existing metastatic disease in a subject using L1CAM inhibition.Type: GrantFiled: January 31, 2019Date of Patent: October 11, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Karuna Ganesh, Manuel Valiente, Joan Massague
-
Publication number: 20220152205Abstract: The present invention relates to methods and compositions for modulating the blood CSF barrier and for diagnosing, preventing and/or treating leptomeningeal metastasis. In particular embodiments of the invention, the permeability of the blood CSF barrier is modulated by agonists or antagonists of Complement Component 3 (C3) or its receptor.Type: ApplicationFiled: February 8, 2022Publication date: May 19, 2022Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Adrienne Boire, Joan Massague
-
Patent number: 11305014Abstract: The present invention relates to methods and compositions for modulating the blood CSF barrier and for diagnosing, preventing and/or treating leptomeningeal metastasis. In particular embodiments of the invention, the permeability of the blood CSF barrier is modulated by agonists or antagonists of Complement Component 3 (C3) or its receptor.Type: GrantFiled: May 18, 2018Date of Patent: April 19, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Adrienne Boire, Joan Massague
-
Publication number: 20220105069Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.Type: ApplicationFiled: June 11, 2021Publication date: April 7, 2022Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Joan Massague, Adrienne Boire, Qing Chen
-
Patent number: 11058665Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.Type: GrantFiled: September 13, 2019Date of Patent: July 13, 2021Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Joan Massague, Adrienne Boire, Qing Chen
-
Publication number: 20200085781Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.Type: ApplicationFiled: September 13, 2019Publication date: March 19, 2020Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Joan Massague, Adrienne Boire, Qing Chen
-
Publication number: 20200032249Abstract: The present invention provides new and improved methods for performing in situ transcriptomics from rare “cells of interest” present in complex multicellular environments. These methods involve expressing a recombinant cytosine deaminase enzyme in the cells of interest, and also supplying an exogenous non-naturally occurring halogenated cytosine substrate for the enzyme—which results in the generation halogenated uridine which is incorporated into RNA, thereby “tagging” RNA in the cells of interest. The invention also provides several variations of such methods that significantly improve the sensitivity and specificity of the RNA labeling. Furthermore, the invention also provides simple and efficient methods for purifying the tagged RNA. The purified tagged RNA can be used to analyze the transcriptomes of the cells of interest by RNA-sequencing and other methods.Type: ApplicationFiled: March 13, 2018Publication date: January 30, 2020Inventors: Harihar BASNET, Joan Massagué
-
Patent number: 10413522Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.Type: GrantFiled: March 17, 2017Date of Patent: September 17, 2019Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Joan Massague, Adrienne Boire, Qing Chen
-
Publication number: 20190167817Abstract: The present invention relates to methods and compositions for inhibiting metastatic spread of cancer and/or inhibiting progression of pre-existing metastatic disease in a subject using L1CAM inhibition.Type: ApplicationFiled: January 31, 2019Publication date: June 6, 2019Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Karuna Ganesh, Manuel Valiente, Joan Massague
-
Publication number: 20180334508Abstract: The present invention relates to methods and compositions for modulating the blood CSF barrier and for diagnosing, preventing and/or treating leptomeningeal metastasis. In particular embodiments of the invention, the permeability of the blood CSF barrier is modulated by agonists or antagonists of Complement Component 3 (C3) or its receptor.Type: ApplicationFiled: May 18, 2018Publication date: November 22, 2018Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Adrienne Boire, Joan Massague
-
Publication number: 20170258758Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.Type: ApplicationFiled: March 17, 2017Publication date: September 14, 2017Applicant: Memorial Sloan-Kettering Cancer CenterInventors: Joan Massague, Adrienne Boire, Qing Chen
-
Patent number: 9546146Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: March 9, 2016Date of Patent: January 17, 2017Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcolm Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
-
Publication number: 20160221984Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: March 9, 2016Publication date: August 4, 2016Inventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcolm Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
-
Publication number: 20160194639Abstract: The present invention relates to methods and compositions for determining whether a cancer patient is at increased risk for developing metastatic spread of the cancer and, if the patient is at increased risk, for treating the patient such that the risk of metastasis is reduced. It is based, at least in part, on the discoveries that overexpression of serpin and serpin secretion by cancer cells and L1CAM-mediated vascular cooption promote metastasis of lung and breast cancer to the brain, and that antagonism of serpin or L1CAM reduced metastasis.Type: ApplicationFiled: March 18, 2016Publication date: July 7, 2016Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Joan Massague, Manuel Valiente
-
Patent number: 9303009Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: April 6, 2012Date of Patent: April 5, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcom Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
-
Publication number: 20150065575Abstract: Determinations of the level of expression of S100A8/A9 protein serve as a prognostic indicator of the therapeutic response to a given type of chemotherapy treatment and as a monitoring indicator of the effectiveness of an on-going chemotherapy treatment for the treatment of breast cancer in human patients. Kits can be used for performing these determinations.Type: ApplicationFiled: March 15, 2013Publication date: March 5, 2015Inventors: Joan Massague, Swarnali Acharyya
-
Patent number: 8906606Abstract: A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.Type: GrantFiled: April 16, 2012Date of Patent: December 9, 2014Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gaorav P. Gupta, Joan Massague, Andy J. Minn
-
Publication number: 20140024705Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: April 6, 2012Publication date: January 23, 2014Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcom Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
-
Publication number: 20120294872Abstract: A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.Type: ApplicationFiled: April 16, 2012Publication date: November 22, 2012Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Gaorav P. Gupta, Joan Massague, Andy J. Minn